Literature DB >> 16041243

Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1).

Isabelle J Létourneau1, Roger G Deeley, Susan P C Cole.   

Abstract

The 190-kDa ATP-binding cassette (ABC) multidrug resistance protein 1 (MRP1) encoded by the MRP1/ABCC1 gene mediates the active cellular efflux of glucuronide, glutathione and sulfate conjugates. It can also confer resistance to a diverse spectrum of chemotherapeutic agents and transport a variety of toxicants. In the present study, we examined 10 MRP1/ABCC1 missense genetic variants [non-synonymous single nucleotide polymorphisms (SNPs)] to determine whether or not they affect expression or function of the transporter. Variants 218C>T (Thr73Ile), 257C>T (Ser92Phe), 350C>T (Thr117Met), 689G>A (Arg230Gln), 1898G>A (Arg633Gln), 2168G>A (Arg723Gln), 2965G>A (Ala989Thr), 3140G>C (Cys1047Ser), 3173G>A (Arg1058Gln) and 4535C>T (Ser1512Leu) were recreated using site-directed mutagenesis and transfected into human embryonic kidney cells. Immunoblotting experiments showed that all mutant proteins were expressed at levels comparable to wild-type MRP1. Vesicular transport assays revealed that the Ala989Thr mutation caused a significant decrease in estradiol 17beta-glucuronide transport due to a decrease in apparent affinity (Km) for this organic anion. The transport properties of the other mutants were comparable to wild-type MRP1. When the MRP1/ABCC1 non-synonymous SNPs were evaluated by the SIFT algorithm using subsets of homologs and orthologs of MRP1/ABCC1, Arg230Gln, Val353Met, Arg433Ser, Gly671Val and Arg1058 mutations were predicted to be deleterious, whereas the PolyPhen algorithm predicted Ser92Phe and Gly671Val to be potentially damaging. Thus most predictions of these algorithms were not in accordance with our experimental results. In conclusion, our data suggest that none of the MRP1/ABCC1 variants studied are likely by themselves to have major deleterious effects in healthy individuals, and the SIFT and PolyPhen algorithms appear to be poor predictors of the phenotypic consequences of these MRP1 mutations at least in vitro.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041243     DOI: 10.1097/01.fpc.0000173484.51807.48

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  23 in total

1.  Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome.

Authors:  Motofumi Tanaka; Taro Okazaki; Hideo Suzuki; James L Abbruzzese; Donghui Li
Journal:  Cancer       Date:  2010-10-04       Impact factor: 6.860

Review 2.  Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.

Authors:  Tristan M Sissung; Sarah M Troutman; Tessa J Campbell; Heather M Pressler; Hyeyoung Sung; Susan E Bates; William D Figg
Journal:  Discov Med       Date:  2012-01       Impact factor: 2.970

3.  PharmGKB summary: methotrexate pathway.

Authors:  Torben S Mikkelsen; Caroline F Thorn; Jun J Yang; Cornelia M Ulrich; Deborah French; Gianluigi Zaza; Henry M Dunnenberger; Sharon Marsh; Howard L McLeod; Kathy Giacomini; Mara L Becker; Roger Gaedigk; James Steven Leeder; Leo Kager; Mary V Relling; William Evans; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

4.  ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.

Authors:  M Li; E L Seiser; R M Baldwin; J Ramirez; M J Ratain; F Innocenti; D L Kroetz
Journal:  Pharmacogenomics J       Date:  2016-11-15       Impact factor: 3.550

Review 5.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

6.  Expression and function of human MRP1 (ABCC1) is dependent on amino acids in cytoplasmic loop 5 and its interface with nucleotide binding domain 2.

Authors:  Surtaj H Iram; Susan P C Cole
Journal:  J Biol Chem       Date:  2010-12-20       Impact factor: 5.157

Review 7.  Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application.

Authors:  Jiye Yin; Jianting Zhang
Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban       Date:  2011-10

Review 8.  Pharmacogenetics of membrane transporters: an update on current approaches.

Authors:  Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg
Journal:  Mol Biotechnol       Date:  2010-02       Impact factor: 2.695

9.  Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.

Authors:  Gabriele Buda; Deborah Ricci; C Chris Huang; Reyna Favis; Nadine Cohen; Sen H Zhuang; Jean-Luc Harousseau; Pieter Sonneveld; Joan Bladé; Robert Z Orlowski
Journal:  Ann Hematol       Date:  2010-06-08       Impact factor: 3.673

10.  Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population.

Authors:  Ji-Ye Yin; Qiong Huang; Youyun Yang; Jian-Ting Zhang; Mei-Zuo Zhong; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Pharmacogenet Genomics       Date:  2009-03       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.